- Home
- ELAB vs AZTR Comparison
ELAB vs AZTR Comparison
Compare ELAB & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELAB
- AZTR
- Stock Information
- Founded
- ELAB 2020
- AZTR 2014
- Country
- ELAB United States
- AZTR United States
- Employees
- ELAB N/A
- AZTR N/A
- Industry
- ELAB
- AZTR Biotechnology: Pharmaceutical Preparations
- Sector
- ELAB
- AZTR Health Care
- Exchange
- ELAB Nasdaq
- AZTR Nasdaq
- Market Cap
- ELAB 3.2M
- AZTR 3.7M
- IPO Year
- ELAB 2023
- AZTR 2023
- Fundamental
- Price
- ELAB $1.98
- AZTR $0.15
- Analyst Decision
- ELAB
- AZTR
- Analyst Count
- ELAB 0
- AZTR 0
- Target Price
- ELAB N/A
- AZTR N/A
- AVG Volume (30 Days)
- ELAB 42.6K
- AZTR 1.0M
- Earning Date
- ELAB 08-13-2025
- AZTR 08-11-2025
- Dividend Yield
- ELAB N/A
- AZTR N/A
- EPS Growth
- ELAB N/A
- AZTR N/A
- EPS
- ELAB N/A
- AZTR N/A
- Revenue
- ELAB N/A
- AZTR N/A
- Revenue This Year
- ELAB N/A
- AZTR N/A
- Revenue Next Year
- ELAB N/A
- AZTR N/A
- P/E Ratio
- ELAB N/A
- AZTR N/A
- Revenue Growth
- ELAB N/A
- AZTR N/A
- 52 Week Low
- ELAB $1.81
- AZTR $0.14
- 52 Week High
- ELAB $546.00
- AZTR $0.80
- Technical
- Relative Strength Index (RSI)
- ELAB 44.44
- AZTR 29.71
- Support Level
- ELAB $1.85
- AZTR $0.14
- Resistance Level
- ELAB $2.01
- AZTR $0.16
- Average True Range (ATR)
- ELAB 0.12
- AZTR 0.01
- MACD
- ELAB -0.00
- AZTR -0.00
- Stochastic Oscillator
- ELAB 34.69
- AZTR 7.69
About ELAB Elevai Labs Inc.
PMGC Holdings Inc advancing in Medical Aesthetics and Biopharmaceutical Innovation. It specializes in Skin Aesthetics, Obesity, and Metabolic Health business.
About AZTR Azitra Inc
Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.